97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR
#602THERAPEUTIC BINDING MOLECULES
#603METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES
#604Chimeric Antigen Receptor-Modified NK-92 Cells
#605MULTIPLEXED IMMUNOHISTOCHEMISTRY USING RECOMBINANT ANTIBODIES WITH EPITOPE TAGS
#606HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE BASED REPORTER ASSAY FOR ANTIGEN DETECTION
#607NEW METHOD TO IMPROVE NK CELLS CYTOTOXICITY
#608SINGLE DOMAIN ANTIBODY AGAINST PD-L1 AND USE THEREOF
#609INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE
#610ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#611ENGINEERED NK CELLS AND USES THEREOF
#612CD8(+) Stem-Like Chronic Memory Cell Based Therapies and Compositions Related Thereto
#613FUSION PROTEIN TARGETING PD-L1 AND NEUTRALIZING GAS6 AND USES THEREOF
#614BI-SPECIFIC ANTIBODIES COMPRISING ANTI-B7H3 BINDING MOLECULES
#615CANCER THERAPY USING CHECKPOINT INHIBITORS
#616IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS
#617MUTATED FERRITIN PROTEIN
#618PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LUNG CANCER
#619NEOANTIGEN ADJUVANT AND MAINTENANCE THERAPY
#620COMBINATION THERAPY BY USING AKR1C3-ACTIVATED COMPOUND WITH IMMUNE CHECKPOINT INHIBITOR
#621INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY
#622POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES
#623BINDING MOLECULES THAT BIND CD137 AND PD-L1
#624ANTI-HUMAN PD-L1 ANTIBODIES AND THEIR USES
#625NEW STABLE ANTI-VISTA ANTIBODY
#626SINGLE DOMAIN PD-L1 ANTIBODIES
#627BI-SPECIFIC ANTIBODIES FOR USE IN PRODUCING ARMED IMMUNE CELLS
#628ANTIBODIES AGAINST TIM3 AND USES THEREOF
#629PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS
#630CHIMERIC COSTIMULATORY RECEPTORS, CHEMOKINE RECEPTORS, AND THE USE OF SAME IN CELLULAR IMMUNOTHERAPIES
#631FLUOROCARBON COMPOSITIONS AND METHODS FOR ENHANCING IMMUNOTHERAPY
#632METHOD FOR TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
#633ANTI-EGFR ANTIBODY DRUG CONJUGATES
#634THERAPEUTIC METHODS USING CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
#635METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
#636CHIMERIC ANTIGEN RECEPTORS, NUCLEIC ACIDS ENCODING THE SAME, AND USES THEREOF IN TREATING CANCERS
#637COMPOSITIONS AND METHODS FOR IMMUNOMODULATORY BIFUNCTIONAL FUSION MOLECULES
#638B7H6 ANTIBODY AND USE THEREOF
#639THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#640TARGETING ANTI-HUMAN PD 1H/VISTA TO TREAT HEMATOLOGIC DISORDERS
#641TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES
#642METHODS OF TREATING TUMOR
#643COMBINATION OF ANTI-GARP ANTIBODY AND IMMUNOMODULATOR
#644Antigen Binding Proteins that Bind PD-L1
#645mRNA display antibody library and methods
#646ENGINEERED INTERLEUKIN-10 AND FUSION PROTEINS THEREOF
#647PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR
#648ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30
#649COMBINATION CANCER THERAPY
#650ANTI-PD-1 ANTIBODIES AND USES THEREOF
#651ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS
#652AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
#653Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
#654MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#655Multi-Specific Molecules
#656ANTIBODY PRODRUGS WITH CONSTANT DOMAINS
#657MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#658ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
#659THERAPEUTIC COMBINATION FOR TREATING CANCER
#660METHODS FOR PREDICTING TREATMENT OUTCOME TO CHECKPOINT INHIBITORS IN CANCER
#661COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME
#662METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#663METHODS FOR MODULATING AN IMMUNE RESPONSE
#664IL18-FC FUSION PROTEINS
#665MUC16 PROMOTER CONTAINING VIRUS
#666VISTA Antagonist and Methods of Use
#667METHODS TO PROTECT TRANSPLANTED TISSUE FROM REJECTION
#668B7-H3 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
#669BIFUNCTIONAL MOLECULE BINDING TO HUMAN TGFß AND PD-L1, AND USE THEREOF
#670ANTI-VSIG4 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND USES THEREOF
#671ANTI-ICOS ANTIBODIES
#672MULTIFUNCTIONAL BTLA EXTRACELLULAR DOMAIN CO-INHIBITORY MOIETY TRAPS TO MODULATE IMMUNE TOLERANCE
#673COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
#674COMBINATORIAL ANDROGEN DEPRIVATION WITH AN ANDROGEN RECEPTOR VACCINE
#675LUNG-CANCER SPECIFIC T CELL DYSFUNCTION
#676COMPOSITIONS AND METHODS FOR TREATING SOLID TUMORS
#677COMBINATION THERAPIES
#678NATURAL KILLER CELL ANTIBODIES WITH INCREASED ADCC ACTIVITY
#679ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS
#680PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
#681ANTI-IGFBP7 CONSTRUCTS AND USES THEREOF
#682ANTI-NKP30 ANTIBODY AND APPLICATION THEREOF
#683MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF
#684GAMMA DELTA T-CELL COSTIMULATION
#685COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE
#686METHODS AND COMPOSITIONS FOR NEOADJUVANT AND ADJUVANT UROTHELIAL CARCINOMA THERAPY
#687ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#688ANTI-VISTA CONSTRUCTS AND USES THEREOF
#689ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#690ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
#691CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
#692METHOD AND COMBINATION FOR TREATING TUMORS
#693COMBINATION THERAPY WITH A VINCA ALKALOID N-OXIDE AND AN IMMUNE CHECKPOINT INHIBITOR
#694HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE BASED REPORTER ASSAY FOR ANTIGEN DETECTION
#695Biomarkers for predicting tumor response to and toxicity of immunotherapy
#696DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#697SINGLE DOMAIN ANTIBODY AGAINST PD-L1 AND USE THEREOF
#698ANTI-VISTA ANTIBODIES AND USES THEREOF
#699ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#700Methods of treating a neoplasia with IL-15-based molecules and CTLA-4 antibody
#701PROTEINS BINDING NKG2D, CD16, AND CEACAM5
#702METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
#703Antibodies Specific for CD47, PD-L1, and Uses Thereof
#704ANTIBODY MOLECULES FOR CANCER TREATMENT
#705SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
#706RETROVIRAL VECTOR FOR UNIVERAL RECEPTOR THERAPY
#707COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
#708ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#709TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#710GARP Protein Antibody and Use Thereof
#711HIV VACCINES AND METHODS OF MAKING AND USING
#712ANTIBODIES TO TIGIT
#713USE OF CLOSTRIDIUM GHONII SPORE COMBINED WITH PEMBROLIZUMAB
#714METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS
#715COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
#716ANTIBODY AND TAXANE COMBINATION THERAPY
#717BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF
#718DUAL TARGETING CHIMERIC ANTIGEN RECEPTORS
#719COMBINATION OF A T CELL THERAPY AND A DGK INHIBITOR
#720TUMOR PHENOTYPE PREDICTION USING GENOMIC ANALYSES INDICATIVE OF DIGITAL-PATHOLOGY METRICS
#721A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR
#722MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME
#723NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER
#724INTERFERON RECEPTOR AGONISTS AND USES THEREOF
#725HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA-GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
#726COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS
#727NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF
#728Treatment of LAG-3 positive tumors
#729B7-H3 NANOBODY, PREPARATION METHOD AND USE THEREOF
#730BISPECIFIC ANTIBODY
#731LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#732Chimeric Antigen Receptor Therapies for Treating Solid Tumors
#733ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY
#734COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS
#735ANTIBODIES BINDING CD40 AND PD-L1 AND USES THEREOF
#736METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4
#737MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO PD-L1
#738METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION
#739METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE
#740Antibody-drug conjugate
#741RECOMBINANT POLYPEPTIDES FOR REGULATABLE CELLULAR LOCALIZATION
#742METHODS OF PREPARING AND EXPANDING TYPE I INNATE LYMPHOID CELLS AND THERAPEUTIC USES THEREOF
#743Halogenated xanthene composition and method for treating hematologic cancers
#744GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN
#745METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#746HER2 ANTIBODY AND APPLICATION THEREOF
#747DEVICE AND METHODS FOR RAPIDLY SCREENING AND TREATING CLINICAL CANCER PATIENTS WITH IMMUNOREGULATORY DRUGS
#748HER-2 targeted bispecific compositions and methods for making and using the same
#749Interferon Prodrugs and Methods of Making and Using the Same
#750ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
#751COMBINATION THERAPIES
#752ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF
#753BISPECIFIC ANTIBODY AND USE THEREOF
#754ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#755COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY
#756METHODS FOR ASSAYING TARGET PROTEINS ON EXTRACELLULAR VESICLES IN PLASMA
#757THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#758ANTI-B7H3 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
#759THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS FOR CANCER
#760MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
#761Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease
#762ANTI-PD-L1/ANTI-CD47 NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF
#763DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN
#764Combination Treatment of Cancer
#765EGANELISIB FOR USE IN THE TREATMENT OF PD-L1 NEGATIVE CANCER
#766B7-H4 ANTIBODIES AND METHODS OF USE THEREOF
#767METHODS FOR TREATING HEMATOLOGIC CANCERS
#768ANTI-B7-H3 ANTIBODY AND USES THEREOF
#769METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE
#770ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF
#771ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
#772CD73 COMPOUNDS
#773IMMUNE CHECKPOINT INHIBITOR CONJUGATED WITH ULTRASONIC SENSITIZER, AND USE THEREOF
#774CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
#775CIRCULATING BIOMARKERS OF RESPONSE TO PD-1/PD-L1 BLOCKADE AND GSK-3 INHIBITION
#776ANTI-PD-L1/ANTI-4-1BB NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMERIC FORM BISPECIFIC ANTIBODY AND PREPARATION THEREOF
#777INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS
#778BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL
#779CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#780DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT
#781Bispecific CD137-binding antibodies for T-cell activation
#782CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS
#783METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-GPC3 ANTIBODIES
#784ANTI-HUMAN PD-L2 ANTIBODIES
#785ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF
#786BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
#787Methods of Treating Cancer with Anti-TIGIT Antibodies
#788USE OF ANTI-IL-27 ANTIBODIES
#789THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
#790METHODS AND COMPOSITIONS FOR PRODUCING TARGETED MICROBUBBLES
#791ANTI-MSLN BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME
#792ONCOLYTIC HERPES SIMPLEX TYPE 1 VIRUSES FOR TREATMENT OF BRAIN TUMORS
#793METHODS OF TREATING CANCER WITH A COMBINATION OF TUCATINIB AND AN ANTI-PD-1/ANTI-PD-L1 ANTIBODY
#794CANCER TREATMENT USING BOSENTAN IN COMBINATION WITH A CHECKPOINT INHIBITOR
#795THERAPEUTIC ANTIBODIES AND THEIR USES
#796METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
#797ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#798CD3 BINDING ANTIBODIES
#799Oncolytic viruses targeting STAT3
#800TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY
#801ANTI-PDL1 ANTIBODY FORMULATIONS
#802BISPECIFIC ANTIBODY AND USE THEREOF
#803PD1-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
#804COMPOSITIONS AND METHODS OF TREATMENT COMPRISING TUMOR-TARGETING BACTERIA AND CHEMOTHERAPY OR IMMUNOTHERAPY AGENT
#805TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS
#806ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY
#807ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY
#808ANTI-PD-L1 ANTIBODIES
#809CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#810Antibody Compositions and Methods of Use Thereof
#811INHIBITORS FOR USE IN TREATING LIVER DISORDERS
#812INHIBITION OF KIR2DL2 FOR THE ENHANCEMENT OF ADOPTIVE IMMUNOTHERAPIES
#813THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE
#814COMPREHENSIVE GENOMIC PROFILING (CGP) OF METASTATIC INVASIVE LOBULAR CARCINOMAS REVEALS HETEROGENEITY
#815TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIES
#816Multivalent and multispecific 41BB-binding proteins
#817Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
#818BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO CANCER IMMUNOTHERAPEUTIC AGENT AND USE THEREOF
#819Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
#820Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
#821STABILIZED ANTIBODY PROTEIN SOLUTIONS
#822Constrained conditionally activated binding proteins
#823METHOD AND COMPOSITON FOR TREATING CANCER USING A VACCINE
#824MATERIALS AND METHODS OF TREATING CANCER
#825BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES
#826MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF
#827ANTI-PD-L1 ANTIBODY AND USE THEREOF
#828FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE
#829UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR PD-LI AND USES THEREOF
#830IMMUNE CHECKPOINT INHIBITOR
#831ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL
#832Human Kynureninase enzymes and uses thereof
#833COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
#834TARGETED THERAPEUTIC AGENTS AND USES THEREOF
#835VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY
#836IL-12 COMPOSITIONS AND METHODS OF USE THEREOF
#837TREATMENT OF MESOTHELIOMA BY ADMINISTRATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE
#838COMPOSITIONS AND METHODS FOR TUMOR CHARACTERIZATION
#839METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
#840ANTIBODY-LIKE PROTEIN AND USE THEREOF
#841COMBINATION TREATMENT
#842COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS
#843DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
#844METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSIS
#845MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS)
#846CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1
#847CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR
#848Anti-CD46 antibodies and methods of use
#849MOLECULES BINDING PD-L1 AND USES THEREOF
#850Antibodies against TIM3 and uses thereof
#851Crystalline forms of a CD73 inhibitor and uses thereof
#852CSF1R KINASE INHIBITOR AND USE THEREOF
#853METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES
#854BIOMARKERS FOR PREDICTING OVERALL SURVIVAL IN RECORRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
#855Methods for modulating an immune response
#856METHODS FOR CONCENTRATING PROTEINS
#857LIVE BIOTHERAPEUTICS SECRETING SYNTHETIC BACTERIOPHAGES IN THE TREATMENT OF CANCER
#858Combination Treatment of Cancer
#859LYOPHILIZED COMPOSITION COMPRISING (S)-ISOPROPYL 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE FOR SUBCUTANEOUS ADMINISTRATION AND THE USE THEREOF
#860BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#861COMBINATION THERAPY FOR TREATING COLORECTAL CANCER
#862CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY
#863ONCOLYTIC HERPES SIMPLEX VIRUSES (HSV) EXPRESSING IMMUNOMODULATORY FUSION PROTEINS
#864CELL SECRETED MINIBODIES AND USES THEREOF
#865IMMUNOSTIMULATORY AGONISTIC ANTIBODIES FOR USE IN TREATING CANCER
#866COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN CANCERS
#867ENGINEERED CELLS AND METHODS OF USE
#868ANTI-VSIG4 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF
#869NOVEL ANTI-PD-1 ANTIBODIES
#870BISPECIFIC ANTIBODY FOR ICOS AND PD-L1
#871MCL1 inhibitors
#8721H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
#873CHIMERIC SWITCH RECEPTORS FOR THE CONVERSION OF IMMUNESUPPRESSIVE SIGNALS TO COSTIMULATORY SIGNALS
#874Therapeutic Bacterial Composition
#875Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
#876METHODS FOR MONITORING AND TREATING CANCER
#877MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT
#878METHOD OF ENHANCING IMMUNE RESPONSE AND CANCER IMMUNOTHERAPY BY TARGETING THE CD58:CD2 AXIS
#879METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY INHIBITION OF FBXO44
#880METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY
#881THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF
#882ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS
#883VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
#884COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1
#885Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
#886METHODS FOR CHARACTERIZING BIOLOGICAL SAMPLES
#887COMBINATION THERAPY USING AN IL-2 RECEPTOR AGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
#888ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS
#889CpG IMMUNOCONJUGATES FOR CANCER THERAPY
#890CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#891ENGINEERING IMMUNE CHECKPOINT BLOCKADE NANOBODY-STING DELTA-TM FUSION PROTEIN AS A VERSATILE TREATMENT FOR SOLID TUMOR CANCERS
#892HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER
#893PROTAC ANTIBODY CONJUGATES AND METHODS OF USE
#894PD-L1 and OX40 binding proteins for cancer regulation
#895Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
#896Bifunctional Proteins Combining Checkpoint Blockade for Targeted Therapy
#897USE OF AN ANTI-PD-1 ANTIBODY AND A CYTOTOXIC ANTICANCER DRUG IN TREATMENT OF NON-SMALL CELL LUNG CANCER
#898Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
#899HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
#900MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF